Literature DB >> 26484906

Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).

Tuan Minh Do1, Agnès Dodacki2,3,4, Wael Alata5, Frederic Calon5, Sophie Nicolic2,3,4, Jean-Michel Scherrmann2,3,4, Robert Farinotti1, Fanchon Bourasset2,3,4.   

Abstract

The involvement of transporters located at the blood-brain barrier (BBB) has been suggested in the control of cerebral Aβ levels, and thereby in Alzheimer's disease (AD). However, little is known about the regulation of these transporters at the BBB in animal models of AD. In this study, we investigated the BBB expression of Aβ influx (Rage) and efflux (Abcb1-Abcg2-Abcg4-Lrp-1) transporters and cholesterol transporter (Abca1) in 3-18-month-old 3xTg-AD and control mice. The age-dependent effect of BBB transporters regulation on the brain uptake clearance (Clup) of [3H]cholesterol and [3H]Aβ1 - 40 was then evaluated in these mice, using the in situ brain perfusion technique. Our data suggest that transgenes expression led to the BBB increase in Aβ influx receptor (Rage) and decrease in efflux receptor (Lrp-1). Our data also indicate that mice have mechanisms counteracting this increased net influx. Indeed, Abcg4 and Abca1 are up regulated in 3- and 3/6-month-old 3xTg-AD mice, respectively. Our data show that the balance between the BBB influx and efflux of Aβ is maintained in 3 and 6-month-old 3xTg-AD mice, suggesting that Abcg4 and Abca1 control the efflux of Aβ through the BBB by a direct (Abcg4) or indirect (Abca1) mechanism. At 18 months, the BBB Aβ efflux is significantly increased in 3xTg-AD mice compared to controls. This could result from the significant up-regulation of both Abcg2 and Abcb1 in 3xTg-AD mice compared to control mice. Thus, age-dependent regulation of several Aβ and cholesterol transporters at the BBB could ultimately limit the brain accumulation of Aβ.

Entities:  

Keywords:  3xTg-AD; ABCA1; ABCB1; ABCG2; ABCG4; Alzheimer’s disease; Oatp1a4; RAGE; amyloid-β; blood-brain barrier; cholesterol

Mesh:

Substances:

Year:  2016        PMID: 26484906     DOI: 10.3233/JAD-150350

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  18 in total

1.  Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.

Authors:  Kati-Sisko Vellonen; Jouni Ihalainen; Marie-Christine Boucau; Fabien Gosselet; Théo Picardat; Mikko Gynther; Katja M Kanninen; Anthony R White; Tarja Malm; Jari Koistinaho; Markus M Forsberg; Marika Ruponen
Journal:  Pharm Res       Date:  2017-09-26       Impact factor: 4.200

2.  Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Izumi Yokoyama; R L Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2018-03-17       Impact factor: 3.478

Review 3.  Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access.

Authors:  Mitchell P McInerney; Jennifer L Short; Joseph A Nicolazzo
Journal:  AAPS J       Date:  2017-05-01       Impact factor: 4.009

4.  Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro.

Authors:  Elvis Cuevas; Hector Rosas-Hernandez; Susan M Burks; Manuel A Ramirez-Lee; Aida Guzman; Syed Z Imam; Syed F Ali; Sumit Sarkar
Journal:  Metab Brain Dis       Date:  2019-07-02       Impact factor: 3.584

5.  Histamine H3 Inverse Agonist BF 2649 or Antagonist with Partial H4 Agonist Activity Clobenpropit Reduces Amyloid Beta Peptide-Induced Brain Pathology in Alzheimer's Disease.

Authors:  Ranjana Patnaik; Aruna Sharma; Stephen D Skaper; Dafin F Muresanu; José Vicente Lafuente; Rudy J Castellani; Ala Nozari; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 6.  The role of amyloid beta clearance in cerebral amyloid angiopathy: more potential therapeutic targets.

Authors:  Xue-Mei Qi; Jian-Fang Ma
Journal:  Transl Neurodegener       Date:  2017-08-17       Impact factor: 8.014

7.  Expression and function of Abcg4 in the mouse blood-brain barrier: role in restricting the brain entry of amyloid-β peptide.

Authors:  Agnès Dodacki; Matthew Wortman; Bruno Saubaméa; Stéphanie Chasseigneaux; Sophie Nicolic; Nathalie Prince; Murielle Lochus; Anne-Laure Raveu; Xavier Declèves; Jean-Michel Scherrmann; Shailendra B Patel; Fanchon Bourasset
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

8.  Effect of rosiglitazone on amyloid precursor protein processing and Aβ clearance in streptozotocin-induced rat model of Alzheimer's disease.

Authors:  Li Wang; Wei Liu; Ying Fan; Tingting Liu; Chunjiang Yu
Journal:  Iran J Basic Med Sci       Date:  2017-05       Impact factor: 2.699

9.  Effect of Linguizhugan decoction on neuroinflammation and expression disorder of the amyloid β‑related transporters RAGE and LRP‑1 in a rat model of Alzheimer's disease.

Authors:  Qianfeng Hu; Beibei Yu; Qinlei Chen; Yi Wang; Yun Ling; Songxian Sun; Yinlong Shi; Chunxiang Zhou
Journal:  Mol Med Rep       Date:  2017-11-06       Impact factor: 2.952

10.  URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Gang Zhang; R Lee Mosley; Harris A Gelbard; Howard E Gendelman
Journal:  J Neuroinflammation       Date:  2018-05-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.